MedTech firm RQM+ acquires Jordi Labs
Healthcare-centred professional services firm RQM+ has acquired Jordi Labs for an undisclosed fee. The purchase will add new capabilities to strengthen RQM+’s regulatory and production services for the medical industry.
According to research by Statista, revenue in the Medical Technology market is projected to reach $575.80 billion in 2022. The market's largest segment is Medical Devices with a projected market volume of $455.10 billion in 2022, while revenue is expected to show an annual growth rate of 5.95% to 2027, resulting in a market volume of $768.80 billion in five-years-time. This means demand for consultants who can help get the most out of this booming sector is booming.
Headquartered in Monroeville, Pennsylvania, RQM+ is a professional services firm with offices in Nottingham in the UK, and Basel in Switzerland. The firm states on LinkedIn it believes it is the world's largest regulatory and clinical consulting firm which focuses on medical devices and diagnostics. It also offers up a raft of MedTech services, supporting market access throughout the entire product lifecycle for medical devices and diagnostics.
As the firm looks to expand its capabilities for growing client demand across North America and Europe, RQM+ has purchased Jordi Labs. The Mansfield, Massachusetts-based company provides chemical characterization and complex product deformulation as well as contaminant and failure investigations to MedTech manufacturers.
“As the only MedTech service provider rooted in almost 40 years of regulatory strategy, RQM+ is proud to now offer expanded proprietary testing services, which gives our customers the fastest path to regulatory approvals,” said CEO Margaret Keegan.
RQM+ – which is a portfolio company of Linden Capital Partners – currently works for eight of the world’s top 10 medical device manufacturers. With its new capabilities from the Jordi Labs deal, RQM+ provides comprehensive regulatory, quality, clinical and laboratory services, supporting market access throughout the entire product lifecycle for medical devices and diagnostics.
“We are delighted to now be a part of the RQM+ solution that brings customers to market faster with our unmatched track record of rapid testing results that satisfy the stringent requirements of regulators globally”, added Mark Jordi, president of Jordi Labs.
Kirkland and Ellis served as legal advisor to Linden Capital Partners. Harris Williams represented Jordi Labs.
